IRadimed (IRMD) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Financial performance and growth outlook

• Achieved $72 million in revenue for 2024, maintaining profitability and paying dividends.

• Revenue split evenly between MRI-safe IV pumps and patient monitors, with both segments showing growth.

• Expects to surpass $100 million in revenue by the end of 2026, driven by a major replacement cycle.

• Anticipates 120%+ growth in 2026 as new pump launches and pent-up demand is addressed.

• Growth expected to remain elevated for five to seven years as installed base is replaced.

Product innovation and competitive positioning

• Only provider of MRI-safe, non-magnetic IV pumps, with significant IP and technical barriers to entry.

• New generation pump features modular design, smart sensing, and user-friendly interface to ease adoption.

• Custom components and proprietary technology make replication by competitors difficult.

• Pump and monitor both use non-magnetic, custom-made parts, with the monitor being much lighter and more portable than legacy devices.

• Gross margins on hardware and disposables are high, around 77%.

Market opportunity and commercial strategy

• Installed base of 11,000–12,000 pump channels, many over five years old and ready for replacement.

• Direct sales force in the U.S. and distributor model internationally; strong control over sales process.

• Replacement market validated by recent campaign: ending extended maintenance on old pumps led to over 500 replacements in 2024.

• Power users (20% of customers) require multiple pumps per MRI, multiplying sales potential.

• Partnerships with GE, Siemens, and Canon provide catalog presence, but most sales are direct.